Navigation Links
InterMune Reports First Quarter 2011 Financial Results and Business Highlights
Date:4/28/2011

2011 (the "Form 10-K"), and other periodic reports filed with the SEC, including but not limited to the following: (i) the fact that physician prescriptions of Actimmune for the treatment of IPF, an indication for which Actimmune has not been approved by the FDA, have declined significantly following the March 2007 termination of the Phase 3 INSPIRE trial of Actimmune in IPF and the risk that InterMune's revenue will continue to decline as expected; (ii) risks related to significant regulatory, supply and competitive barriers to entry with respect to Actimmune; (iii) risks related to the uncertain, lengthy and expensive clinical development process for the company's product candidates, including having no unexpected safety, toxicology, clinical or other issues and having no unexpected clinical trial results such as unexpected new clinical data and unexpected additional analysis of existing clinical data; (iv) risks related to the regulatory process for the company's product candidates, including the possibility that the results of the ASCEND phase 3 clinical trial may not be satisfactory to the FDA for InterMune to receive regulatory approval for pirfenidone in the United States; (v) risks related to unexpected regulatory actions or delays or government regulation generally; (vi) risks related to the company's manufacturing strategy, which relies on third-party manufacturers and which exposes InterMune to additional risks where it may lose potential revenue; (vii) government, industry and general public pricing pressures; and (viii) InterMune's ability to obtain or maintain patent or other proprietary intellectual property protections.  The risks and other factors discussed above should be considered only in connection with the fully discussed risks and other factors discussed in detail in the Form 10-K and InterMune's other periodic reports filed with the SEC, all of which are available via InterMune's web site at www.inter
'/>"/>

SOURCE InterMune, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. InterMune to Present at Canaccord Adams Conference
2. InterMune Earns Development Milestone in HCV Protease Inhibitor Collaboration With Roche
3. InterMune to Present Four Abstracts on HCV Protease Inhibitor ITMN-191 at the AASLD Meeting
4. InterMune Reports Japanese Regulatory Approval of Pirfenidone in IPF
5. InterMune to Release Third Quarter 2008 Financial Results on November 6
6. InterMune Reports Third Quarter 2008 Financial Results and Business Highlights
7. InterMune to Present at Deutsche Bank Biotech Boston Confab
8. InterMune to Present at J.P. Morgan Healthcare Conference
9. InterMune Reports Results of Two Phase 3 CAPACITY Studies of Pirfenidone in IPF
10. InterMune Announces Pricing of Public Offering of 3,500,000 Shares of Common Stock
11. InterMune Announces Issuance of U.S. Patent for ITMN-191
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/23/2014)... (PRWEB) September 23, 2014 Marktech Optoelectronics ... deep ultra violet emitters in the 280 nm wavelength ... UV emitters which range from 280nm to 405nm. These ... water sanitation as well as curing. Mark Campito, Marktech’s ... of special interest to manufacturers is that we offer ...
(Date:9/23/2014)... September 23, 2014 The Minnesota ... developer of cellular modems , platforms and ... the Startup category for the 2014 Tekne Awards. ... at the Minneapolis Convention Center on Thursday, November ... individuals who have shown superior technology innovation and ...
(Date:9/22/2014)... (PRWEB) September 22, 2014 Pearl's Premium ... breakthrough in drought tolerant grass seed this week with ... seed. The announcement coincides with the fact that it ... Spring as many believe. , As of the ... and favorable reviews by industry experts and the media ...
(Date:9/22/2014)... by researchers at the USC Viterbi School of ... 3-D microfluidic system quickly and cheaply by simply ... Microfluidic systems are used in many fields including ... volumes of fluids for use in applications such ... diagnostic testing, and synthetic chemistry. Traditionally, microfluidic devices ...
Breaking Biology Technology:Marktech Introduces its New Line of Deep UV Emitters 2NimbeLink Named Finalist for 15th Annual Tekne Awards 2NimbeLink Named Finalist for 15th Annual Tekne Awards 3Pearl's Premium Ultra Low Maintenance Lawn Seed Announces A Major Breakthrough In Drought Tolerant Grass Seed 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 2Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 3Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 4Lego-like modular components make building 3-D 'labs-on-a-chip' a snap 5
... , Chemosaturation Demonstrates Clinically Meaningful Tumor ... Delcath Systems, Inc. (NASDAQ: DCTH ... tumor (mNET) cohort of the Company,s recently completed Phase ... and Interventional Radiological Society of Europe (CIRSE) congress ...
... N.Y. A new system to be installed ... enable exciting new research possibilities across the nation ... modeling and simulation, data science, high-performance computing, and ... million grant from the National Science Foundation (NSF) ...
... All ABC Members and Members of the Herb and ... that I inform you of the passing of our ... Saturday evening, September 10, per the tribute we have ... Director, American Botanical Council, Editor, HerbalGram & HerbClip ...
Cached Biology Technology:Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE 2Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE 3Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE 4Positive Phase 2 Trial Results from Neuroendocrine Tumor Cohort Presented at CIRSE 5New supercomputer to boost Rensselaer leadership in high-performance computing 2New supercomputer to boost Rensselaer leadership in high-performance computing 3New supercomputer to boost Rensselaer leadership in high-performance computing 4Norman R. Farnsworth, Renowned Medicinal Plant Researcher, Dies at 81 2Norman R. Farnsworth, Renowned Medicinal Plant Researcher, Dies at 81 3Norman R. Farnsworth, Renowned Medicinal Plant Researcher, Dies at 81 4Norman R. Farnsworth, Renowned Medicinal Plant Researcher, Dies at 81 5Norman R. Farnsworth, Renowned Medicinal Plant Researcher, Dies at 81 6Norman R. Farnsworth, Renowned Medicinal Plant Researcher, Dies at 81 7
(Date:9/23/2014)... fragments called "jumping genes" that insert themselves into DNA ... phenomenon can result in age-related diseases such as cancer. ... that the "jumping genes" in mice become active as ... them in check in order to take on another ... Nature Communications , Professor of Biology Vera Gorbunova ...
(Date:9/22/2014)... new American Cancer Society study suggests that participants ... known as the food stamp program, had lower ... The authors say the findings emphasize the need ... quality of SNAP participants. , The SNAP program ... the resources to obtain a nutritionally adequate diet. ...
(Date:9/22/2014)... researchers are studying a potential new treatment that reverses ... which scars develop in the lungs and severely hamper ... which is delivered to lung tissue intravenously. In mouse ... fibrosis after several days. , The findings were ... Medicine . , "The mimic, when injected into the ...
Breaking Biology News(10 mins):A multi-function protein is key to stopping genomic parasites from 'jumping' 2Federal food program puts food on the table, but dietary quality could be improved 2Reversing the effects of pulmonary fibrosis 2
... the Upper Paraguay River and its tributaries, is the largest ... of organisms and it is an ark for large populations ... Pantanal fulfills a large range of ecosystem services that are ... seasonal floodplain system, plants, animals, and local human populations show ...
... cover all from the historical aspects of the beaver ... the development of reintroduced or recovering populations, consequences of ... beavers, relationship with animal and plant communities on land ... the high degree to which the beaver is able ...
... (Nicols Prez Hidalgo and M. Pilar Mier Durante) have ... Matsumura ) in Madrid, Spain from a photography displayed ... ) (ngel Umaran). The results have been published recently ... are available for free download. "This discovery is ...
Cached Biology News:
Sigmas E-TOXATE (Limulus Amebocyte Lysate) test kits are intended for the detection and semiquantitation,of endotoxins for research purposes....
...
... versatile enclosures are designed ... or other process gas ... environment. HEPA filtration, heating/cooling, ... modules also available, along ...
... Staccato Series of systems provide fast and ... , genomics, proteomics and drug development laboratories. ... configurations; Mini Workstation Series, Application Series and ... Station is a remarkably compact system for ...
Biology Products: